Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IPPS Rule Lowers FY 2005 Add-On Threshold, Denies InFuse Application

This article was originally published in The Gray Sheet

Executive Summary

CMS' decision to lower the cost threshold for new devices to qualify for technology "add-on" payments under the IPPS assumes that the number of applications for the additional reimbursement will remain sparse

You may also be interested in...



New Tech “Add-On” Payments Sought By Hospital On Behalf Of Firms

CardiacAssist hopes to obtain new technology "add-on" inpatient reimbursement for its TandemHeart percutaneous vascular assist device (PVAD), which will be used in an estimated 200 cardiogenic shock cases in 2005

New Tech “Add-On” Payments Sought By Hospital On Behalf Of Firms

CardiacAssist hopes to obtain new technology "add-on" inpatient reimbursement for its TandemHeart percutaneous vascular assist device (PVAD), which will be used in an estimated 200 cardiogenic shock cases in 2005

First Device Qualifies For Add-On Payment; CMS Retains Proposed Threshold

The device industry's hopes to reduce the Centers for Medicare & Medicaid Services' new technology "add-on" payment threshold are riding on a provision in the House's "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel